BT3 Stock Overview
A clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Lineage Cell Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.56 |
| 52 Week High | US$1.23 |
| 52 Week Low | US$0.48 |
| Beta | 1.18 |
| 1 Month Change | 9.71% |
| 3 Month Change | -27.10% |
| 1 Year Change | n/a |
| 3 Year Change | -69.29% |
| 5 Year Change | -25.17% |
| Change since IPO | -67.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| BT3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 19.7% | 6.5% | 1.3% |
| 1Y | n/a | -1.9% | 9.0% |
Return vs Industry: Insufficient data to determine how BT3 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how BT3 performed against the German Market.
Price Volatility
| BT3 volatility | |
|---|---|
| BT3 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BT3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine BT3's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 72 | Brian Culley | www.lineagecell.com |
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
Lineage Cell Therapeutics, Inc. Fundamentals Summary
| BT3 fundamental statistics | |
|---|---|
| Market cap | €113.87m |
| Earnings (TTM) | -€19.52m |
| Revenue (TTM) | €8.46m |
13.5x
P/S Ratio-5.8x
P/E RatioIs BT3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BT3 income statement (TTM) | |
|---|---|
| Revenue | US$8.72m |
| Cost of Revenue | -US$2.31m |
| Gross Profit | US$11.03m |
| Other Expenses | US$31.14m |
| Earnings | -US$20.11m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.091 |
| Gross Margin | 126.54% |
| Net Profit Margin | -230.66% |
| Debt/Equity Ratio | 0% |
How did BT3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 01:10 |
| End of Day Share Price | 2025/01/09 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lineage Cell Therapeutics, Inc. is covered by 11 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Gum-Ming Lowe | Craig-Hallum Capital Group LLC |